Page 38 - Expanded Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease

RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease - read this article along with other careers information, tips and advice on BioSpace

United statesFoster rosenblattDaniellet abramsonRedhill biopharmaAdi frishRedhill biopharma ltdLarge us managed care health planExchange commissionCompany annual report on formTrademark officeCompany expanded access programCompany codesResearch priorities for pulmonary nontuberculous mycobacteriaCorporate business developmentAmerican lung associationNon tuberculosis mycobacteria

FDA Agrees to Expanded Access Program for the BioVentrix® Revivent TC® System for the Treatment of Ischemic Heart Failure

/PRNewswire/ BioVentrix®, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated.

New yorkUnited statesJerryd estepJim dillonPrnewswire bioventrixPopulation health sciencesIcahn school of medicine at mount sinaiBioventrix incDrug administrationInvestigational use onlyAccess programProvide opportunityTreat additional patientsExpanded access programLess invasive ventricular enhancementBioventrix revivent

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for adagrasib in combination with cetuximab in patients with KRASG12C-mutated advanced colorectal cancer whose. | December 21, 2022

Alan sandlerRona yaegerPrnewswire mirati therapeutics incDrug administrationMirati therapeutics incExchange commissionPhysician at memorial sloan kettering cancer centerAccess programBreakthrough therapy designationNew england journalClinical resultsAssociate attending physicianMemorial sloan kettering cancer centerChief medicalAccelerated approvalTime oncology review

Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab

Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomBritish columbiaNeil josephsonStacie lindseyZymework azymetricAsia pacificDiana papoveJack spinksSiegel rlet alJazz pharmaceuticals ireland limitedZymeworks incGuidelines committeeBeigene ltdExchange commissionSecurities exchange

Zymeworks (ZYME) Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab

Zymeworks (ZYME) Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNeil josephsonStacie lindseyZymework azymetricAsia pacificDiana papoveJack spinksSiegel rlet alJazz pharmaceuticals ireland limitedZymeworks incGuidelines committeeBeigene ltdExchange commissionSecurities exchangeCholangiocarcinoma foundationAccess program